2,323 research outputs found
Role of spatial coherence in polarization tomography
We analyze an experimental setup in which a quasi-monochromatic spatially
coherent beam of light is used to probe a paraxial optical scatterer. We
discuss the effect of the spatial coherence of the probe beam on the Mueller
matrix representing the scatterer. We show that according to the degree of
spatial coherence of the beam, the \emph{same} scattering system can be
represented by \emph{different} Mueller matrices. This result should serve as a
warning for experimentalists.Comment: 3 pages, 1 figur
Cellulases from Mycelial fungi <em>Penicillium verruculosum</em> as a Real Alternative to Trichoderma Enzymes in Industrial Hydrolysis of Cellulosic Biomass
Abstract The possibility of using the recipient strain Penicillium verruculosum B1-537 (ÎniaD) as a producer of laboratory and industrial enzymes was considered. The advantage of this strain is its ability to secrete a basic cellulase complex consisting of cellobiohydrolases, endoglucanases, and ÎČ-glucosidase, which exceeds in its hydrolytic ability the enzyme complex of Hypocrea (Trichoderma) strains. Using the expression system, the basic complex of cellulases of the recipient strain Piptochaetium verruculosum B1-537 (ÎniaD) was supplemented with new (booster) enzymes that are necessary to increase its hydrolytic activity. Enzyme preparations adapted to the processing of various types of renewable plant biomass were obtained
Efficacy and safety of diacerein in patients with knee osteoarthritis
Diacerein (D) belongs to a class of symptomatic slow-acting agents, has an original mechanism of action, and is widely used as a diseasemodifying antirheumatic drug to treat osteoarthritis (OA) in Russia and many countries of the world. The ability of the drug to affect the main symptoms and progression of OA has been shown in a number of well-organized clinical trials.Objective: to evaluate the efficacy and safety of D in patients with knee OA.Patients and methods. An open-label trial evaluating the efficacy and safety of D (diaflex) in patients with knee OA was conducted in accordance with the multicenter program «Osteoarthrosis: Assessment of Progression in Real Clinical Practice». The trial included 80 patients of both sexes with Stage IIâIII knee OA; mean age, 60.8±6.8 years (47â75 years); mean body mass index, 31.8±5.9 kg/m2; disease duration, 10.3±5.7 years (2â30 years). The duration of the trial was 9 months (6 months of therapy and 3 months of follow-up).Results. There was a statistically significant reduction in visual analog scale pain on walking just 1 month after therapy initiation (57.1±9.7 and 44.7±13.9 mm; p<0.0001) and a further significant improvement throughout the 6-month therapy. Pain did not increase after the drug was discontinued (the follow-up period was 3 months). The same pattern was observed in the assessment of the WOMAC index (pain during early therapy, 243.8±73.9; pain at the end of therapy, 137.5±78.9; stiffness, 97.8±41.1 and 57.7±38.6; functional failure, 875.8±250.4 and 525±305.7 respectively; p<0.0001). Statistically significantly improved quality of life indicators measured by EQ-5D were noted throughout the follow-up period: 0.43±0.23 at the beginning of therapy, 0.61±0.14 at its end, and 0.63±0.11 at 3 months following treatment completion (p<0.0001). By the time of therapy completion, 71.3% of the patients completely refused to take nonsteroidal anti-inflammatory drugs (NSAIDs). Both the patient and the physician evaluated the efficiency of treatment identically. By the end of therapy, 87.5% of the patients were observed to have improvement. Adverse reactions (ARs) were recorded in 10 (12.5%) patients and mainly associated with more frequent stools; ARs were not a cause of treatment interruptions or protocol deviations.Conclusion. Diaflex has a good symptomatic and anti-inflammatory effect: the therapy statistically significantly reduces pain, stiffness, and the need for NSAIDs and improves quality of life and joint function. The drug has a good safety profile and after-effects, which is seen at least 3 months after therapy discontinuation
ĐĄŃĐ°ĐČĐœĐžŃДлŃĐœŃĐč Đ°ĐœĐ°Đ»ĐžĐ· ĐżĐŸĐșĐ°Đ·Đ°ŃДлДĐč ĐșĐ°ŃĐ”ŃŃĐČĐ° лДĐșĐ°ŃŃŃĐČĐ”ĐœĐœĐŸĐłĐŸ ĐżŃДпаŃĐ°ŃĐ° Đ°Đ»ŃбŃĐŒĐžĐœĐ° ŃĐ”Đ»ĐŸĐČĐ”ĐșĐ° Ń ĐžĐ·ĐŒĐ”ĐœĐ”ĐœĐœŃĐŒ ŃŃабОлОзОŃŃŃŃĐžĐŒ ŃĐŸŃŃĐ°ĐČĐŸĐŒ
Scientific relevance. The national and international human albumin preparations registered in the Russian Federation mainly differ in their excipient compositions. While all the international preparations of human albumin contain a mixture of sodium caprylate and N-acetyl-DL-tryptophan, the Russian ones contain only sodium caprylate. However, albumin stabilisation with sodium caprylate at high concentrations affects the ligand-binding properties of albumin. For this reason, as well as to achieve storage stability not only at temperatures of 2 °C to 8 °C but also  at room temperature, most international manufacturers have reduced the sodium caprylate content in albumin preparations and added N-acetyl-DL-tryptophan. This demonstrates the relevance of studying the quality of a new Russian human albumin preparation with a modified stabilising composition, including both sodium caprylate and N-acetyl-DL-tryptophan.Aim. The study aimed at comparing several quality attributes of the human albumin preparation with a modified stabilising composition with those of imported human albumin preparations.Materials and methods. The human albumin preparation with a modified stabilising composition was manufactured by fractionation from donor plasma meeting the requirements of monograph FS.3.3.2.0001.19 of the State Pharmacopoeia of the Russian Federation edition XIV. The quality control was in line with the monograph on human albumin (FS.3.3.2.0006.18), and statistical analysis was conducted in Microsoft Excel in accordance with the general chapter on statistical analysis (OFS.1.1.0013.15).Results. The study preparation complied with the requirements specified in monograph FS.3.3.2.0006.18. All the manufactured batches were clear, thermostable, sterile, and non-pyrogenic. The prekallikrein activator levels were low (below 1 IU/mL). The aluminium content varied from 30.36±10.39 ”g/L to 50.22±6.94 ”g/L. The study preparation contained sodium ions at a concentration from 127.44±10.46 mmol/L to 145.59±7.32 mmol/L and less than 0.01 mmol/g of potassium ions. The osmolarity exceeded 240 mOsm/L. The content of α- and ÎČ-globulins ranged from 1.79±0.06% to 2.24±0.20%. The study preparation had a pH level of 6.9 to 7.2. The concentrations of polymers and aggregates did not exceed 0.5%.Conclusions. The quality attributes studied suggest that the human albumin preparation with  a modified stabilising composition is comparable to its international counterparts and that it meets Russian and European pharmacopoeial standards.ĐĐșŃŃĐ°Đ»ŃĐœĐŸŃŃŃ. ĐĐ°ŃŃĐ±Đ”Đ¶ĐœŃĐ” лДĐșĐ°ŃŃŃĐČĐ”ĐœĐœŃĐ” ĐżŃДпаŃĐ°ŃŃ Đ°Đ»ŃбŃĐŒĐžĐœĐ° ŃĐ”Đ»ĐŸĐČĐ”ĐșĐ°, Đ·Đ°ŃДгОŃŃŃĐžŃĐŸĐČĐ°ĐœĐœŃĐ” ĐČ Đ ĐŸŃŃĐžĐčŃĐșĐŸĐč ЀДЎДŃĐ°ŃОО, ĐŸŃлОŃĐ°ŃŃŃŃ ĐŸŃ ĐŸŃĐ”ŃĐ”ŃŃĐČĐ”ĐœĐœŃŃ
глаĐČĐœŃĐŒ ĐŸĐ±ŃĐ°Đ·ĐŸĐŒ ĐżĐŸ ŃĐŸŃŃĐ°ĐČŃ ĐČŃĐżĐŸĐŒĐŸĐłĐ°ŃДлŃĐœŃŃ
ĐČĐ”ŃĐ”ŃŃĐČ. ĐŃĐ” ĐžĐœĐŸŃŃŃĐ°ĐœĐœŃĐ” ĐżŃДпаŃĐ°ŃŃ Đ°Đ»ŃбŃĐŒĐžĐœĐ° ŃĐŸĐŽĐ”ŃĐ¶Đ°Ń ŃĐŒĐ”ŃŃ ĐČŃĐżĐŸĐŒĐŸĐłĐ°ŃДлŃĐœŃŃ
ĐČĐ”ŃĐ”ŃŃĐČ â ĐœĐ°ŃŃĐžŃ ĐșĐ°ĐżŃОлаŃĐ° Đž N-Đ°ŃĐ”ŃОл-DL-ŃŃОпŃĐŸŃĐ°ĐœĐ°; ĐŸŃĐ”ŃĐ”ŃŃĐČĐ”ĐœĐœŃĐ” â ŃĐŸĐ»ŃĐșĐŸ ĐœĐ°ŃŃĐžŃ ĐșĐ°ĐżŃОлаŃ. ĐĐŽĐœĐ°ĐșĐŸ ŃŃабОлОзаŃĐžŃ ŃĐ°ŃŃĐČĐŸŃĐ° Đ°Đ»ŃбŃĐŒĐžĐœĐ° ĐœĐ°ŃŃĐžŃ ĐșĐ°ĐżŃОлаŃĐŸĐŒ ĐČ ĐČŃŃĐŸĐșĐžŃ
ĐșĐŸĐœŃĐ”ĐœŃŃĐ°ŃĐžŃŃ
ĐżŃĐžĐČĐŸĐŽĐžŃ Đș ŃŃ
ŃĐŽŃĐ”ĐœĐžŃ Đ”ĐłĐŸ Đ»ĐžĐłĐ°ĐœĐŽŃĐČŃĐ·ŃĐČĐ°ŃŃĐžŃ
ŃĐČĐŸĐčŃŃĐČ. ĐĐŸ ŃŃĐŸĐč ĐżŃĐžŃĐžĐœĐ”, Đ° ŃĐ°ĐșжД ĐŽĐ»Ń ĐŽĐŸŃŃĐžĐ¶Đ”ĐœĐžŃ ŃŃабОлŃĐœĐŸŃŃĐž ĐżŃДпаŃĐ°ŃĐŸĐČ ĐżŃĐž Ń
ŃĐ°ĐœĐ”ĐœĐžĐž ĐœĐ” ŃĐŸĐ»ŃĐșĐŸ ĐżŃĐž ŃĐ”ĐŒĐżĐ”ŃĐ°ŃŃŃĐ” ĐŸŃ 2 ĐŽĐŸ 8 °C, ĐœĐŸ Đž ĐżŃĐž ĐșĐŸĐŒĐœĐ°ŃĐœĐŸĐč ŃĐ”ĐŒĐżĐ”ŃĐ°ŃŃŃĐ”, Đ±ĐŸĐ»ŃŃĐžĐœŃŃĐČĐŸ Đ·Đ°ŃŃĐ±Đ”Đ¶ĐœŃŃ
ĐżŃĐŸĐžĐ·ĐČĐŸĐŽĐžŃДлДĐč ĐžĐ·ĐŒĐ”ĐœĐžĐ»Đž ŃĐŸŃŃĐ°ĐČ ĐżŃДпаŃĐ°ŃĐ° Đ°Đ»ŃбŃĐŒĐžĐœĐ° ĐżŃŃĐ”ĐŒ ŃĐœĐžĐ¶Đ”ĐœĐžŃ ŃĐŸĐŽĐ”ŃĐ¶Đ°ĐœĐžŃ ĐœĐ°ŃŃĐžŃ ĐșĐ°ĐżŃОлаŃĐ° Đž ĐŽĐŸĐżĐŸĐ»ĐœĐžŃДлŃĐœĐŸĐłĐŸ ĐČĐČĐ”ĐŽĐ”ĐœĐžŃ N-Đ°ŃĐ”ŃОл-DL-ŃŃОпŃĐŸŃĐ°ĐœĐ°. Đ ŃĐČŃĐ·Đž Ń ŃŃĐžĐŒ Đ°ĐșŃŃĐ°Đ»ŃĐœŃĐŒ ĐżŃДЎŃŃĐ°ĐČĐ»ŃĐ”ŃŃŃ ĐžĐ·ŃŃĐ”ĐœĐžĐ” ĐżĐŸĐșĐ°Đ·Đ°ŃДлДĐč ĐșĐ°ŃĐ”ŃŃĐČĐ° ŃĐ°Đ·ŃĐ°Đ±ĐŸŃĐ°ĐœĐœĐŸĐłĐŸ ĐŸŃĐ”ŃĐ”ŃŃĐČĐ”ĐœĐœĐŸĐłĐŸ ĐżŃДпаŃĐ°ŃĐ° Đ°Đ»ŃбŃĐŒĐžĐœĐ° ŃĐ”Đ»ĐŸĐČĐ”ĐșĐ° Ń ĐžĐ·ĐŒĐ”ĐœĐ”ĐœĐœŃĐŒ ŃŃабОлОзОŃŃŃŃĐžĐŒ ŃĐŸŃŃĐ°ĐČĐŸĐŒ, ŃĐŸĐŽĐ”ŃжаŃĐžĐŒ ĐŸĐ±Đ° ŃĐșĐ°Đ·Đ°ĐœĐœŃŃ
ĐșĐŸĐŒĐżĐŸĐœĐ”ĐœŃĐ°.ЊДлŃ. ĐĐœĐ°Đ»ĐžĐ· ĐżĐŸĐșĐ°Đ·Đ°ŃДлДĐč ĐșĐ°ŃĐ”ŃŃĐČĐ° ĐżŃДпаŃĐ°ŃĐ° Đ°Đ»ŃбŃĐŒĐžĐœĐ° ŃĐ”Đ»ĐŸĐČĐ”ĐșĐ° Ń ĐžĐ·ĐŒĐ”ĐœĐ”ĐœĐœŃĐŒ ŃŃабОлОзОŃŃŃŃĐžĐŒ ŃĐŸŃŃĐ°ĐČĐŸĐŒ ĐČ ŃŃĐ°ĐČĐœĐ”ĐœĐžĐž Ń Đ·Đ°ŃŃĐ±Đ”Đ¶ĐœŃĐŒĐž лДĐșĐ°ŃŃŃĐČĐ”ĐœĐœŃĐŒĐž ŃŃДЎŃŃĐČĐ°ĐŒĐž.ĐĐ°ŃĐ”ŃĐžĐ°Đ»Ń Đž ĐŒĐ”ŃĐŸĐŽŃ. ĐĐșŃĐžĐČĐœĐŸĐč ŃĐ°ŃĐŒĐ°ŃĐ”ĐČŃĐžŃĐ”ŃĐșĐŸĐč ŃŃбŃŃĐ°ĐœŃОДĐč ĐŽĐ»Ń ĐżĐŸĐ»ŃŃĐ”ĐœĐžŃ ĐżŃДпаŃĐ°ŃĐ° Đ°Đ»ŃбŃĐŒĐžĐœĐ° ŃĐ”Đ»ĐŸĐČĐ”ĐșĐ° Ń ĐžĐ·ĐŒĐ”ĐœĐ”ĐœĐœŃĐŒ ŃŃабОлОзОŃŃŃŃĐžĐŒ ŃĐŸŃŃĐ°ĐČĐŸĐŒ ŃĐ»ŃжОла ĐżĐ»Đ°Đ·ĐŒĐ° ĐșŃĐŸĐČĐž ĐŽĐŸĐœĐŸŃĐŸĐČ, ŃĐŸĐŸŃĐČĐ”ŃŃŃĐČŃŃŃĐ°Ń ŃŃĐ”Đ±ĐŸĐČĐ°ĐœĐžŃĐŒ ĐĐŸŃŃĐŽĐ°ŃŃŃĐČĐ”ĐœĐœĐŸĐč ŃĐ°ŃĐŒĐ°ĐșĐŸĐżĐ”Đž Đ ĐŸŃŃĐžĐčŃĐșĐŸĐč ЀДЎДŃĐ°ŃОО XIV ОзЎ. (ĐĐ€ РЀ XIV) ЀХ.3.3.2.0001.19. ĐŃДпаŃĐ°Ń ĐżĐŸĐ»ŃŃалО ĐŒĐ”ŃĐŸĐŽĐŸĐŒ ŃŃĐ°ĐșŃĐžĐŸĐœĐžŃĐŸĐČĐ°ĐœĐžŃ Đ±Đ”Đ»ĐșĐŸĐČ ĐżĐ»Đ°Đ·ĐŒŃ ĐșŃĐŸĐČĐž. ĐĐŸĐœŃŃĐŸĐ»Ń ĐżĐŸĐșĐ°Đ·Đ°ŃДлДĐč ĐșĐ°ŃĐ”ŃŃĐČĐ° ĐżŃДпаŃĐ°ŃĐ° ĐŸŃŃŃĐ”ŃŃĐČĐ»ŃлО ĐČ ŃĐŸĐŸŃĐČĐ”ŃŃŃĐČОО Ń ŃŃĐ”Đ±ĐŸĐČĐ°ĐœĐžŃĐŒĐžÂ Đ€ĐĄ.3.3.2.0006.18. ХŃĐ°ŃĐžŃŃĐžŃĐ”ŃĐșŃŃ ĐŸĐ±ŃĐ°Đ±ĐŸŃĐșŃ ĐżŃĐŸĐČĐŸĐŽĐžĐ»Đž Ń ĐżĐŸĐŒĐŸŃŃŃ ĐżŃĐŸĐłŃĐ°ĐŒĐŒŃ Microsoft Excel ĐČ ŃĐŸĐŸŃĐČĐ”ŃŃŃĐČОО Ń ĐЀХ.1.1.0013.15.РДзŃĐ»ŃŃĐ°ŃŃ. ĐĐŸĐșĐ°Đ·Đ°ĐœĐŸ ŃĐŸĐŸŃĐČĐ”ŃŃŃĐČОД ĐżĐŸĐșĐ°Đ·Đ°ŃДлДĐč ĐșĐ°ŃĐ”ŃŃĐČĐ° ĐžŃŃлДЎŃĐ”ĐŒĐŸĐłĐŸ ĐżŃДпаŃĐ°ŃĐ° ŃŃŃĐ°ĐœĐŸĐČĐ»Đ”ĐœĐœŃĐŒ ŃŃĐ”Đ±ĐŸĐČĐ°ĐœĐžŃĐŒÂ Đ€ĐĄ.3.3.2.0006.18. Đ Ń
ĐŸĐŽĐ” ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐč  ŃŃŃĐ°ĐœĐŸĐČĐ»Đ”ĐœĐŸ, ŃŃĐŸ ĐžĐ·ĐłĐŸŃĐŸĐČĐ»Đ”ĐœĐœŃĐ” ŃĐ”ŃОО пŃДпаŃĐ°ŃĐ° бŃлО ĐżŃĐŸĐ·ŃĐ°ŃĐœŃĐŒĐž, ŃĐ”ŃĐŒĐŸŃŃабОлŃĐœŃĐŒĐž, ŃŃĐ”ŃОлŃĐœŃĐŒĐžÂ Đž апОŃĐŸĐłĐ”ĐœĐœŃĐŒĐž; ĐžĐŒĐ”Đ»Đž ĐœĐžĐ·ĐșĐžĐč ŃŃĐŸĐČĐ”ĐœŃ Đ°ĐșŃĐžĐČĐ°ŃĐŸŃĐ° ĐżŃĐ”ĐșаллОĐșŃĐ”ĐžĐœĐ° â ĐŒĐ”ĐœĐ”Đ” 1 ĐĐ/ĐŒĐ»; ŃĐŸĐŽĐ”ŃĐ¶Đ°ĐœĐžĐ” Đ°Đ»ŃĐŒĐžĐœĐžŃ Đ±ŃĐ»ĐŸ ĐČ ĐŽĐžĐ°ĐżĐ°Đ·ĐŸĐœĐ” ĐŸŃ 30,36±10,39 ĐŽĐŸÂ 50,22±6,94Â ĐŒĐșĐł/Đ»;Â ĐœĐ°ŃŃĐžĐč-ĐžĐŸĐœĐ° â ĐŸŃ 127,44±10,46 ĐŽĐŸ 145,59±7,32 ĐŒĐŒĐŸĐ»Ń/Đ»; ĐșалОĐč-ĐžĐŸĐœĐ° â ĐŒĐ”ĐœĐ”Đ” 0,01 ĐŒĐŒĐŸĐ»Ń/Đł; ĐŸŃĐŒĐŸĐ»ŃŃĐœĐŸŃŃŃ â Đ±ĐŸĐ»Đ”Đ” 240 ĐŒĐŃĐŒ/Đ». ĐŃДпаŃĐ°Ń ŃĐŸĐŽĐ”Ńжал ĐŸŃ 1,79±0,06 ĐŽĐŸ 2,24±0,20% ĐżŃĐžĐŒĐ”ŃĐ”Đč ĐŽŃŃгОŃ
бДлĐșĐŸĐČ (α- Đž ÎČ-ĐłĐ»ĐŸĐ±ŃĐ»ĐžĐœĐŸĐČ); ĐżĐŸĐșĐ°Đ·Đ°ŃĐ”Đ»Ń ŃРбŃĐ» ĐČ ĐŽĐžĐ°ĐżĐ°Đ·ĐŸĐœĐ” ĐŸŃ 6,9 ĐŽĐŸ 7,2; ĐșĐŸĐœŃĐ”ĐœŃŃĐ°ŃĐžŃ ĐżĐŸĐ»ĐžĐŒĐ”ŃĐŸĐČ   О Đ°ĐłŃДгаŃĐŸĐČ ĐœĐ” ĐżŃĐ”ĐČŃŃала 0,5%.ĐŃĐČĐŸĐŽŃ. ĐĐŸ ОзŃŃĐ”ĐœĐœŃĐŒ ĐżĐŸĐșĐ°Đ·Đ°ŃДлŃĐŒ ĐșĐ°ŃĐ”ŃŃĐČĐ° ĐżŃДпаŃĐ°Ń Đ°Đ»ŃбŃĐŒĐžĐœĐ° ŃĐ”Đ»ĐŸĐČĐ”ĐșĐ°Â ŃÂ ĐžĐ·ĐŒĐ”ĐœĐ”ĐœĐœŃĐŒ ŃŃабОлОзОŃŃŃŃĐžĐŒ ŃĐŸŃŃĐ°ĐČĐŸĐŒ бŃĐ» ŃĐŸĐżĐŸŃŃĐ°ĐČĐžĐŒ Ń Đ·Đ°ŃŃĐ±Đ”Đ¶ĐœŃĐŒĐž Đ°ĐœĐ°Đ»ĐŸĐłĐ°ĐŒĐž Đž ŃĐŸĐŸŃĐČĐ”ŃŃŃĐČĐŸĐČĐ°Đ» ŃŃĐ”Đ±ĐŸĐČĐ°ĐœĐžŃĐŒ ĐĐ€ РЀ XIV Đž ĐĐČŃĐŸĐżĐ”ĐčŃĐșĐŸĐč ŃĐ°ŃĐŒĐ°ĐșĐŸĐżĐ”Đž
The Electron Calorimeter (ECAL) Long Duration Balloon Experiment
Accurate measurements of the cosmic ray electron energy spectrum in the energy region 50 GeV to greater than 1 TeV may reveal structure caused by the annihilation of exotic dark matter particles and/or individual cosmic ray sources. Here we describe a new long duration balloon (LDB) experiment, ECAL, optimized to directly measure cosmic ray electrons up to several TeV. ECAL includes a double layer silicon matrix, a scintillating optical fiber track imager, a neutron detector and a fully active calorimeter to identify more than 90% of the incident electrons with an energy resolution of about 1.7% while misidentifying only 1 in 200,000 protons and 0.8% of secondary gamma rays as electrons. Two ECAL flights in Antarctica are planned for a total exposure of 50 days with the first flight anticipate for December 2009
Measurement of the cross-section and charge asymmetry of bosons produced in proton-proton collisions at TeV with the ATLAS detector
This paper presents measurements of the and cross-sections and the associated charge asymmetry as a
function of the absolute pseudorapidity of the decay muon. The data were
collected in proton--proton collisions at a centre-of-mass energy of 8 TeV with
the ATLAS experiment at the LHC and correspond to a total integrated luminosity
of 20.2~\mbox{fb^{-1}}. The precision of the cross-section measurements
varies between 0.8% to 1.5% as a function of the pseudorapidity, excluding the
1.9% uncertainty on the integrated luminosity. The charge asymmetry is measured
with an uncertainty between 0.002 and 0.003. The results are compared with
predictions based on next-to-next-to-leading-order calculations with various
parton distribution functions and have the sensitivity to discriminate between
them.Comment: 38 pages in total, author list starting page 22, 5 figures, 4 tables,
submitted to EPJC. All figures including auxiliary figures are available at
https://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/STDM-2017-13
Search for chargino-neutralino production with mass splittings near the electroweak scale in three-lepton final states in âs=13âTeV pp collisions with the ATLAS detector
A search for supersymmetry through the pair production of electroweakinos with mass splittings near the electroweak scale and decaying via on-shell W and Z bosons is presented for a three-lepton final state. The analyzed proton-proton collision data taken at a center-of-mass energy of âs=13ââTeV were collected between 2015 and 2018 by the ATLAS experiment at the Large Hadron Collider, corresponding to an integrated luminosity of 139ââfbâ1. A search, emulating the recursive jigsaw reconstruction technique with easily reproducible laboratory-frame variables, is performed. The two excesses observed in the 2015â2016 data recursive jigsaw analysis in the low-mass three-lepton phase space are reproduced. Results with the full data set are in agreement with the Standard Model expectations. They are interpreted to set exclusion limits at the 95% confidence level on simplified models of chargino-neutralino pair production for masses up to 345 GeV
Measurement of inclusive D*+- and associated dijet cross sections in photoproduction at HERA
Inclusive photoproduction of D*+- mesons has been measured for photon-proton
centre-of-mass energies in the range 130 < W < 280 GeV and a photon virtuality
Q^2 < 1 GeV^2. The data sample used corresponds to an integrated luminosity of
37 pb^-1. Total and differential cross sections as functions of the D*
transverse momentum and pseudorapidity are presented in restricted kinematical
regions and the data are compared with next-to-leading order (NLO) perturbative
QCD calculations using the "massive charm" and "massless charm" schemes. The
measured cross sections are generally above the NLO calculations, in particular
in the forward (proton) direction. The large data sample also allows the study
of dijet production associated with charm. A significant resolved as well as a
direct photon component contribute to the cross section. Leading order QCD
Monte Carlo calculations indicate that the resolved contribution arises from a
significant charm component in the photon. A massive charm NLO parton level
calculation yields lower cross sections compared to the measured results in a
kinematic region where the resolved photon contribution is significant.Comment: 32 pages including 6 figure
- âŠ